BriaCell Therapeutics Corp. SEC filings BCTXL

BriaCell Therapeutics Corp. has 324 filings in SEC EDGAR's recent list, going back to Jun 20, 2014. Its latest annual report, Form 10-K, was filed on Oct 28, 2026 for the period ended Jul 31, 2026. The latest quarterly report (Form 10-Q) was filed on Jun 9, 2026, covering the quarter ended Apr 30, 2026. The most recent current report (Form 8-K) was filed on Jun 26, 2026 (regulation fd disclosure). The company's fiscal year ends on July 31.

Form Description Filed Period
10-Q Quarterly report Jun 9, 2026 Apr 30, 2026
10-Q Quarterly report Mar 10, 2026 Jan 31, 2026
10-Q Quarterly report Dec 11, 2025 Oct 31, 2025
10-Q Quarterly report Jun 16, 2025 Apr 30, 2025
10-Q Quarterly report Mar 12, 2025 Jan 31, 2025
10-Q Quarterly report Dec 16, 2024 Oct 31, 2024
10-Q Quarterly report Jun 14, 2024 Apr 30, 2024
10-Q Quarterly report Mar 18, 2024 Jan 31, 2024
10-Q Quarterly report Dec 14, 2023 Oct 31, 2023
10-Q Quarterly report Jun 14, 2023 Apr 30, 2023
10-Q Quarterly report Mar 16, 2023 Jan 31, 2023
10-Q Quarterly report Dec 14, 2022 Oct 31, 2022

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BCTX (Nasdaq), BCTXL (Nasdaq), BCTXZ (Nasdaq)
Fiscal year ends
July 31
Incorporated in
British Columbia, Canada
Headquarters
West Vancouver, British Columbia, Canada
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1610820
Former names
Ansell Capital Corp. (until Jun 20, 2014)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.